Melanie Saville

Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.

Dr. Saville is a physician specializing in virology with more than 25 years of experience developing and licensing vaccines working in the private and non-profit sector. Her contributions over the past 25 years have included the development of vaccines for seasonal and pandemic influenza, pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, HIV, ExPEC, pneumococcal disease and SARS-CoV-2.

Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College, London and is a Fellow of the Academy of Medical Sciences, UK.